nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.03.2009 | Original Article

Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na⁺,K⁺-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B

verfasst von: Zunaid Ahmed, Yoshiaki Deyama, Yoshitaka Yoshimura, Kuniaki Suzuki

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cisplatin (CDDP) is one of the major chemotherapeutic drugs, but tumor cells’ acquired resistance to CDDP limits its therapeutic potentials. One of the main reasons of resistance is reduced drug accumulation. The mechanism by which tumor cells accumulate reduced CDDP is not well elucidated yet. The aim of this study was to investigate what regulates intracellular CDDP accumulation.

Methods

Six different types of oral squamous carcinoma cells were used in this study. Assessment of CDDP sensitivity was determined by measuring the ATP level of the cells. Intracellular CDDP and copper (Cu) accumulation were measured and CDDP efflux study was conducted. Assessment of Na⁺,K⁺-ATPase α and β subunits, ATP7A and ATP7B was done by western blotting. Specific activities of Na⁺,K⁺-ATPase and copper-transporting P-type ATPase (Cu²⁺-ATPase) were detected and a role of Na⁺,K⁺-ATPase inhibitor in intracellular CDDP accumulation was examined.

Results

Among the cells HSC-3 and BHY cells were found most CDDP-sensitive and CDDP-resistant, respectively. The most CDDP-sensitive HSC-3 cells exhibited an increased intracellular cisplatin accumulation, high Na⁺,K⁺-ATPase activity and over-expressed Na⁺,K⁺-ATPase α and β subunits, ATP7A and ATP7B, compared to the most CDDP-resistant BHY cells, but there were no such differences between the two in the CDDP efflux level or Cu²⁺-ATPase activity. Moreover, pretreatment with Na⁺,K⁺-ATPase inhibitor markedly reduced intracellular cisplatin accumulation.

Conclusions

Na⁺,K⁺-ATPase activity is responsible for regulating intracellular CDDP accumulation in oral squamous carcinoma cells rather than Cu²⁺-ATPase.

Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2451–2466CrossRef

Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320PubMedCrossRef

Safaei R, Katano K, Samimi G, Holzer AK, Naerdemann W, Howell SB (2004) Contribution of endocytic pathways to the uptake of cisplatin in sensitive and resistant ovarian cancer cells. Proc Am Assoc Cancer Res 45:120

Katano K, Kondo A, Safaei R, Holzer AK, Samimi G, Mishima M et al (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559–6565PubMed

Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M et al (2004) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53:239–246PubMedCrossRef

Safaei R, Holzer AK, Katano K, Samimi G, Howell SB (2004) The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 98:1607–1613PubMedCrossRef

Rakowski RF, Gadsby DC, De Weer P (1989) Stoichiometry and voltage dependence of the sodium pump in voltage-clamped internally dialyzed squid giant axon. J Gen Physiol 93:903–941PubMedCrossRef

Robinson JD, Flashner MS (1979) The Na⁺+K⁺-activated ATPase. Enzymatic and transport properties. Biochim Biophys Acta 549:145–176PubMed

Andrews PA, Mann SC, Huynh HH, Albright KD (1991) Role of the Na⁺,K⁺-ATPase in the accumulation of cis-diammine-dichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 51:3677–3681PubMed

10.

Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, Nishi Y et al (2006) Role of Na⁺,K⁺-ATPase α1 subunit in the intracellular accumulation of cisplatin. Cancer Chemother Pharmacol 57:84–90PubMedCrossRef

11.

Solioz M, Vulpe C (1996) CPx-type ATPase: a class of p-type ATPases that pump heavy metals. Trends Biochem Sci 21:237–241PubMed

12.

Culotta VC, Lin SJ, Schmidt P, Klomp LW, Casareno RL, Gitilin J (1999) Intercellular pathways of copper trafficking in yeast and humans. Adv Exp Med Biol 448:247–254PubMed

13.

Katano K, Safaei R, Samimi G, Holzer AK, Rochdi M, Howell SB (2003) The copper export pumpATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64:466–473PubMedCrossRef

14.

Samimi G, Katano K, Holzer AK, Safaei R, Howell SB (2004) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66:25–32PubMedCrossRef

15.

Safaei R, Howell SB (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:13–23PubMedCrossRef

16.

Jorgensen PL (1988) Purification of Na⁺,K⁺-ATPase: enzyme sources, preparative problems, and preparation from mammalian kidney. Methods Enzymol 156:29–43PubMedCrossRef

17.

Vasallo PM, Post RL (1986) Calcium ion as a probe of the monovalent cation center of sodium, potassium ATPase. J Biol Chem 261:16957–16962PubMed

18.

Ahmed Z, Deyama Y, Yoshimura Y, Suzuki K. Cisplatin inhibits Na⁺,K⁺-ATPase activity depending on its concentration, preincubation time and temperature. Hokkaido J Dent Sci (in press)

19.

Chifflet S, Torriglia A, Chiesa R, Tolosa S (1988) A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPase. Anal Biochem 168:1–4PubMedCrossRef

20.

Takeda K, Ushimaru M, Fukushima Y, Kawamura M (1999) Characterization of a P-type ATPase of mouse liver microsomes. J Membr Biol 170:13–16PubMedCrossRef

21.

Mellish KJ, Kelland LR, Harrap KR (1993) In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68:240–250PubMed

22.

Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF et al (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47:689–697PubMedCrossRef

23.

Zhengdong L, Duhong B (1995) Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer. Chin Med J 109:353–355

24.

Andrews PA, Velury S, Mann SC, Howell SB (1988) Cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68–73PubMed

25.

Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation is a major mechanism of acquired resistance to cisplatin in a human ovarian cell line: circumvention studies using novel platinum(II) and (IV) ammine/amine complexes. Br J Cancer 66:1109–1115PubMed

26.

Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, Jaehde U (2007) Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73:298–307PubMedCrossRef

27.

Paeker RJ, Eastman A, Bostick-Bruton F, Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87:772–777CrossRef

28.

Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298–14302PubMedCrossRef

29.

Lee J, Maria Marjorette OP, Nose Y, Thiele DJ (2002) Biochemical characterization of the human copper transporter CTR1. J Biol Chem 227:4380–4387CrossRef

30.

Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA et al (2003) Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 88:1327–1334PubMedCrossRef

31.

Bereta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, Perego P (2004) Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and–resistant cells. Biochem Pharmacol 68:283–291CrossRef

32.

Chao CC (1994) Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum (II) in cervix carcinoma HeLa cells: relation to DNA repair. Mol Pharmacol 45:1137–1144PubMed

33.

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M et al (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10:4661–4669PubMedCrossRef

34.

Safaei R (2006) Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 234:34–39PubMedCrossRef

35.

Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T et al (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60:1312–1316PubMed

36.

Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M, Takebayashi Y (2001) Expression and cisplatin sensitivity of copper transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8:1285–1287PubMed

37.

Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che X et al (2007) Copper-transporting P-Type ATPase, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 67:4860–4868PubMedCrossRef

38.

Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M et al (2005) Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129:1454–1463PubMedCrossRef

39.

Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y et al (2006) Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25:2328–2338PubMedCrossRef

40.

Lingrel JB, Kuntzweiler T (1994) Na⁺,K⁺-ATPase. J Biol Chem 269:19659–19662PubMed

41.

Rose AM, Valdes R Jr (1994) Understanding the sodium pump and its relevance to disease. Clin Chem 40:1674–1685PubMed

42.

Bando T, Fujimura M, Kasahara K, Matsuda T (1998) Significance of Na⁺,K⁺-ATPase on intracellular accumulation of cis-diamminedichloroplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 18:1085–1089PubMed

43.

Lizuka N, Miyamoto K, Tangoku A, Hayashi H, Hazama S, Yoshino S et al (2000) Downregulation of intracellular nm23–H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na⁺,K⁺-ATPase. Br J Cancer 83:1209–1215PubMedCrossRef

44.

Ohmori T, Nishio K, Ohta S, Kubota N, Adachi M, Komiya K, Saijo N (1994) Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP). Int J Cancer 57:111–116PubMedCrossRef

Titel: Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B
verfasst von: Zunaid Ahmed
Yoshiaki Deyama
Yoshitaka Yoshimura
Kuniaki Suzuki
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0781-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na⁺,K⁺-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells

Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report

Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer

Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B

Inhibition of NF-κB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie